Author: Timpani, Cara A.; Rybalka, Emma
Title: Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19 Cord-id: zqofac6h Document date: 2020_12_26
ID: zqofac6h
Snippet: COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis
Document: COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis and psoriasis, dimethyl fumarate is an immunomodulatory, anti-inflammatory and anti-oxidative drug that could be rapidly implemented into the clinic to calm the cytokine storm which drives severe COVID-19.
Search related documents:
Co phrase search for related documents- acetylcholine receptor and acute ards respiratory distress syndrome: 1, 2
- acetylcholine receptor and acute lung injury: 1, 2, 3, 4, 5
- acetylcholine receptor and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5
- acetylcholine receptor and lung inflammation: 1, 2, 3
- acetylcholine receptor and lung injury: 1, 2, 3, 4, 5, 6
- acetylcholine receptor and lung tissue injury: 1
- acetylcholine receptor and macrophage cell line: 1
- acid receptor and acute ards respiratory distress syndrome: 1
- acid receptor and acute lung injury: 1
- acid receptor and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- acid receptor and lung inflammation: 1, 2
- acid receptor and lung injury: 1, 2, 3
- acid receptor and lymphocyte neutrophil: 1
- acid receptor and lymphocyte neutrophil ratio: 1
- acid receptor and macrophage activation: 1
- acute ards respiratory distress syndrome and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and lung cancer cell: 1
- acute ards respiratory distress syndrome and lung infiltrate: 1
- acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
Co phrase search for related documents, hyperlinks ordered by date